$PLTR

Jobs Numbers Set for Release Next Week

The article lists upcoming U.S. and Canada economic releases and scheduled earnings for the week. Key data include U.S. manufacturing and services PMIs, job openings, ADP and the employment report, and initial jobless claims. It also cites quarterly EPS figures for companies such as PLTR, VRTX, MAR, AMD, CAT, LLY, NVO, and COP, among others.

Original reporting
Published Aug 3, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 6:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jobs Numbers Set for Release Next Week — source image
Decision brief

The 30-second read

$PLTRNeutralLow
01

Why it matters

It can help traders plan event risk around jobs-related macro prints and multiple earnings dates, but it does not disclose any new company results, guidance, or policy decisions.

02

Market read

Primary value is event timing for macro and earnings volatility, not new fundamental information.

03

What to watch

Actual market impact will depend on the surprise versus consensus at release time, which this article does not provide.

Relevance 4/10Novelty 2/10Timing: next-week earnings and US/Canada labor and jobs-related releases

Background

The piece is a next-week economic and earnings lookahead, listing scheduled US and Canada data releases and featured earnings names.

Company-level read

Ticker impact

$PLTRNeutralLow confidence
Context

The calendar lists Palantir Q2 EPS of 28 cents versus 13 cents prior-year, but provides no new results or guidance.

Expected impact

Limited immediate impact from this article alone; volatility risk exists only when the actual earnings print arrives.

Evidence & confidence

The text is a next-week preview with no new company-specific event beyond the scheduled earnings reference.

$VRTXNeutralLow confidence
Context

Vertex Q2 EPS is listed as 34 cents versus 32 cents prior-year, presented as a featured earnings item.

Expected impact

No actionable price impact from the preview itself.

Evidence & confidence

The article does not report a new print, guidance change, or management update.

$MARNeutralLow confidence
Context

Marriott Q2 EPS is listed as $3.06 versus $2.65 prior-year in the featured earnings section.

Expected impact

Preview-only, so expected impact is minimal until the actual report.

Evidence & confidence

No new data beyond the calendar-style listing.

$AMDNeutralLow confidence
Context

Advanced Micro Devices is listed for Q3 EPS of $1.35 versus 27 cents prior-year, as part of the Tuesday featured earnings.

Expected impact

Potential volatility around the actual earnings date, but not attributable to this article.

Evidence & confidence

No earnings results, guidance, or management commentary are provided.

$CATNeutralLow confidence
Context

Caterpillar Q2 EPS is listed as $6.25 versus $4.72 prior-year in the featured earnings lineup.

Expected impact

No immediate trading signal from the calendar entry alone.

Evidence & confidence

The article does not report a new print or corporate action.

$MRKNeutralLow confidence
Context

Merck Q2 EPS is listed as a loss of 26 cents versus a gain of $2.13 prior-year, as a featured earnings item.

Expected impact

Trading impact depends on the actual earnings release, not on this preview.

Evidence & confidence

No new results, guidance, or regulatory updates are disclosed.

$LLYNeutralLow confidence
Context

Eli Lilly is listed for Q2 EPS of $6.71 versus $6.31 prior-year in the Wednesday featured earnings.

Expected impact

No actionable impact until the earnings report is released.

Evidence & confidence

The article provides no fresh company event or datapoint beyond the calendar listing.

$NVONeutralLow confidence
Context

Novo Nordisk is listed for Q2 EPS of 81 cents versus 97 cents prior-year in the Wednesday featured earnings.

Expected impact

Limited impact from the preview itself.

Evidence & confidence

No new guidance, trial update, or earnings result is reported.

Market effects

Broad earnings calendar across software, semis, industrials, and healthcare, but without new sector-specific catalysts.

US and Canada macro releases (jobs, claims, GDP, PMI/services) can drive cross-asset risk sentiment.

Limited direct global linkage beyond standard macro and earnings scheduling.

Counterpoint

Because this is only a calendar preview, traders may overreact to the listed prior-year comparisons that are not forecasts or new disclosures.

Key entities

  • U.S. employment report (July)

    Scheduled for Friday, with the article framing it as the key jobs-related event.

  • Initial jobless claims (Aug 1)

    Scheduled for Thursday, a near-term labor-market risk catalyst.

  • Featured earnings (multiple tickers)

    A list of companies expected to report across Monday to Friday.

Related articles

$MUHighAI 8/10

Cathie Wood Says the Memory Chip Trend Is Up but the Cycles Are ‘Vicious’

ARK Invest's Cathie Wood warned about volatility in memory chip makers like Micron (MU) and SanDisk (SNDK) due to competition, particularly from China. Both stocks have seen significant gains but recent declines. Micron's Q4 2026 gross margin was 87.0%, up from 45.7% a year earlier. SanDisk's margin rose to 84.6% in Q4 2026 from 22.5% in Q3 2025. Both companies have long-term contracts to mitigate downturns.

$LLYMed

Lebrikizumab relieves ‘debilitating’ symptoms of hand, foot dermatitis in phase 3 study

Lilly's lebrikizumab (Ebglyss) showed significant efficacy in treating atopic hand and foot dermatitis in a phase 3b study. Over 53% of participants achieved clearance by week 16, with improvements in itch, pain, and quality of life. The trial involved 221 adolescents and adults, with no new safety concerns reported. According to the study, lebrikizumab demonstrated statistically significant improvements in symptoms.

$MRKMed

Pennsylvania secures $4 billion in investments, governor says

Pennsylvania Governor Josh Shapiro announced $4 billion in life sciences and private-sector investments. Merck committed $2.9 billion for expansion, including $550 million for a robotics and AI facility. GSK pledged over $800 million for a biopharmaceutical hub. State and federal funds will support port expansions, totaling $837.5 million. These investments are expected to create 6,300 jobs.

$LLYMedAI 8/10

Eli Lilly's Omvoh Shows Promising Phase 3 Results for Ulcerative

Eli Lilly (LLY) reported positive phase 3 trial results for Omvoh in treating ulcerative colitis and Crohn’s disease, showing significant improvements over placebo. The company's stock is modestly undervalued by 19.4% according to GF Value™, with a GF Score™ of 96. Insider activity shows significant selling, while 25 premium gurus hold positions in LLY.

$CATMed

Caterpillar Inc. Announces Management Changes

Caterpillar Inc. announced Denise Johnson, group president of Resource Industries, will retire in February 2027. Derrick York, currently president of Solar Turbines, will replace her in November 2026. Johnson led the division through a downturn and improved its financial performance. York has held various leadership roles within the company since 2007.